Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $47.40 Average Target Price from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRXGet Free Report) has received a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $46.10.

Several research firms recently issued reports on PCRX. Piper Sandler reiterated an “overweight” rating and set a $42.00 target price on shares of Pacira BioSciences in a research report on Wednesday, July 3rd. Needham & Company LLC restated a “buy” rating and set a $43.00 price target on shares of Pacira BioSciences in a report on Tuesday, July 2nd. Barclays cut Pacira BioSciences from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $38.00 to $25.00 in a report on Wednesday, July 3rd. Finally, HC Wainwright restated a “buy” rating and set a $57.00 price target on shares of Pacira BioSciences in a report on Tuesday, July 2nd.

Check Out Our Latest Report on PCRX

Pacira BioSciences Stock Performance

NASDAQ:PCRX opened at $20.96 on Wednesday. The company has a current ratio of 5.81, a quick ratio of 4.78 and a debt-to-equity ratio of 0.57. Pacira BioSciences has a 12-month low of $20.25 and a 12-month high of $40.16. The stock has a 50-day moving average price of $28.31 and a 200 day moving average price of $29.48. The stock has a market capitalization of $975.69 million, a P/E ratio of 14.66 and a beta of 0.88.

Pacira BioSciences (NASDAQ:PCRXGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pacira BioSciences had a return on equity of 12.98% and a net margin of 10.34%. The business had revenue of $167.12 million for the quarter, compared to analysts’ expectations of $165.43 million. Equities research analysts forecast that Pacira BioSciences will post 2.13 EPS for the current fiscal year.

Insider Transactions at Pacira BioSciences

In other news, insider Jonathan Slonin sold 2,836 shares of Pacira BioSciences stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the completion of the transaction, the insider now owns 95,557 shares in the company, valued at approximately $2,699,485.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Kristen Williams sold 7,452 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $28.38, for a total transaction of $211,487.76. Following the completion of the sale, the insider now directly owns 102,912 shares of the company’s stock, valued at approximately $2,920,642.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Slonin sold 2,836 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the sale, the insider now directly owns 95,557 shares of the company’s stock, valued at $2,699,485.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,150 shares of company stock worth $602,170. 6.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pacira BioSciences

Institutional investors and hedge funds have recently modified their holdings of the business. ICA Group Wealth Management LLC bought a new stake in shares of Pacira BioSciences during the 4th quarter worth approximately $30,000. GAMMA Investing LLC lifted its stake in shares of Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after acquiring an additional 932 shares during the last quarter. Park Place Capital Corp bought a new stake in shares of Pacira BioSciences during the 2nd quarter worth approximately $46,000. Quadrant Capital Group LLC raised its position in Pacira BioSciences by 61.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,324 shares of the company’s stock valued at $78,000 after purchasing an additional 885 shares in the last quarter. Finally, Natixis bought a new stake in Pacira BioSciences during the 1st quarter valued at $95,000. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Company Profile

(Get Free Report

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.

Read More

Analyst Recommendations for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.